GlobalData on MSN2d
MindMed doses first subject in trial of tablets for generalised anxiety disorder
US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of ...
MedPage Today2d
Cymbalta Bottles Recalled; 1 in 3 Older Adults Are Lonely; Walking Off Depression
(JAMA Network Open) MindMed announced that the first-ever phase III trial of lysergide D-tartrate (LSD) is underway, ...
Business Wire3d
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...
Mind Med: First patient dosed in Voyage study of LSD in treatment of GAD
Mind Medicine (MNMD) or MindMed announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically ...
Marijuana Moment3d
First Patient Dosed In Historic Study On Whether LSD Effectively Treats Anxiety
For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized ...
ETF Daily News5d
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Position Increased by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. grew its holdings in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free ...
MindMed加入纳斯达克生物技术指数
纽约 - 专注于开发脑健康疾病治疗方法的生物制药公司Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)被选入纳斯达克生物技术指数 (NBI)。该公司将于2024年12月23日开盘时正式纳入指数。目前，该公司市值约5.3亿美元，根据 InvestingPro 分析，其财务健康状况获得FAIR评级。
Business Insider3d
MindMed Begins Phase 3 LSD Study for Anxiety
Mind Medicine (MNMD) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...